Table 1.
Patient demographics
| Treatment Group (N = 288) | HMA + VEN (n = 28) | HMA (n = 47) | Intensive induction (n = 228) | P |
|---|---|---|---|---|
| Median age, y | 71 | 72 | 55 | .0001 |
| <55 | — | — | 114 | |
| 55-65 | 2 | 8 | 89 | |
| >65 | 26 (median, 72) | 39 (median, 75) | 25 (median, 68) | .004* |
| Performance status | ||||
| 0-1 | 15 (63) | 23 (64) | 180 (87) | .0002 |
| 2-3 | 9 (37) | 13 (36) | 27 (13) | |
| AML subtype | ||||
| De novo | 25 (89) | 35 (74) | 213 (93) | .001 |
| Secondary AML | 1 (4) | 6 (13) | 4 (2) | — |
| Treated secondary AML | 2 (7) | 6 (13) | 11 (5) | — |
| Risk group (ELN) | ||||
| Favorable | 24 (86) | 33 (70) | 183 (80) | .310 |
| Intermediate | — | 5 (11) | 12 (5) | — |
| Adverse | 4 (14) | 9 (19) | 33 (15) | — |
| Cytogenetics | ||||
| Diploid | 23 (82) | 28 (60) | 173 (76) | .331 |
| Complex | 1 (4) | 2 (4) | 8 (4) | — |
| +8 | 2 (8) | 1(2) | 7 (3) | |
| −5q | — | — | — | |
| −7q | — | — | 1 (<1) | |
| −5/−7 | — | — | — | |
| 11q abnormality | 1 (<1) | |||
| Other intermediate | 2 (7) | 11 (23) | 23 (1) | |
| Insufficient/not performed | — | 5 (11) | 11 (5) | |
| CBF (inv(16), t(8;21)) | — | — | 4 (2) |
Data are n or n (%) unless otherwise noted.
*
HMA + VEN vs IC.